Intervention Targets and New Drug Development for Ischemic Stroke;

Molecular Regulatory Mechanisms of Blood-Brain Barrier Dysfunction Induced by Ischemic Stroke;

Research on Targeted Drugs for Central Nervous System Inflammation Associated with Blood-Brain Barrier Dysfunction;

2016.09 - 2019.06: Joint PhD program of Shenyang Pharmaceutical University and Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Major: Pharmacology;

2013.09 - 2016.07: China Medical University, Major: Pharmacology;

2009.09 - 2013.07: Shenyang Pharmaceutical University, Major: Traditional Chinese Pharmacy;

2024.01 - Now, Shenzhen Institutes of Advanced Technolgy, Chinese Academy of Sciences, Associate Professor;

2019.08 - 2021.08, Shenzhen Institutes of Advanced Technolgy, Chinese Academy of Sciences, Postdoc;

2019.08 - 2024.01, Shenzhen Institutes of Advanced Technolgy, Chinese Academy of Sciences, Assistant Professor;

   

(1). Yang Hongchun#, Ibrahim MM#, Zhang Siyu, Sun Yao, Chang Junlei, Qi Hui^*, Yang Shilun*. Targeting post-stroke neuroinflammation with Salvianolic acid A: molecular mechanisms and preclinical evidence. Frontiers in Immunology. 2024 Jul 30;15:1433590；

(2) Yang Shilun; Xu Dingkang; Zhang Dianhui; Huang Xiaowen; Li Simeng; Wang Yan; Lu Jing; Wang Daming; Guo Zhen-Ni; Yang Yi; Ye Dewei; Wang Yu; Xu Aimin; Ruby Lai Chong Hoo*; Chang Junlei* ; Levofloxacin alleviates blood-brain barrier disruption following cerebral ischemia and reperfusion via directly inhibiting A-FABP, European Journal of Pharmacology, 2023, 963；

(3) Yang, Shilun; Wang, Haigang; Yang, Yinglin; Wang, Rui; Wang, Yuehua; Wu, Chunfu*; Du, Guanhua* ; Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage, Biomedicine & Pharmacotherapy, 2019, 117；

(4) Yang, Shilun#; Li, Simeng#; Chang, Junlei* ; Discovery of Cobimetinib as a novel A-FABP inhibitor using machine learning and molecular docking-based virtual screening, RSC Advances, 2022, 12(21): 13500-13510；

(5) Yang, Shilun; Shen, Yanjia; Lu, Wendan; Yang, Yinglin; Wang, Haigang; Li, Li; Wu, Chunfu*; Du, Guanhua* ; Evaluation and Identification of the Neuroprotective Compounds of Xiaoxuming Decoction by Machine Learning: A Novel Mode to Explore the Combination Rules in Traditional Chinese Medicine Prescription, Biomed Research International, 2019, 2019: 0-6847685；

(6) Liao, Boya#; Yang, Shilun#; Geng, Leiluo; Zong, Jiuyu; Zhang, Zixuan; Jiang, Mengxue; Jiang, Xue; Li, Simeng; Xu, Aimin; Chang, Junlei*; Hoo, Ruby Lai Chong* ; Development of a therapeutic monoclonal antibody against circulating adipocyte fatty acid binding protein to treat ischemic stroke, British Journal of Pharmacology, 2023, 181(8): 1238-1255；

(7) Yu Min#; Nie Yage#; Yang Jiawen#; Yang Shilun#; Li Rui; Rao Varsha; Hu Xiaoyan; Fang Cheng; Li Simeng; Song Dengpan; Guo Fuyou; Snyder Michael P.; Chang Howard Y.; Kuo Calvin J.*; Xu Jin*; Chang Junlei* ; Integrative multi-omic profiling of adult mouse brain endothelial cells and potential implications in Alzheimer's disease, Cell Reports, 2023, 42(11): 0-113392；

(8) Ma Yinzhong#; Yang Shilun#; He Qianyan; Zhang Dianhui; Chang Junlei* ; The Role of Immune Cells in Post-Stroke Angiogenesis and Neuronal Remodeling: The Known and the Unknown, Frontiers in Immunology, 2021, 12(784098)；

(9). Huang Xiaowen#, Wei Pengju#, Fang Cheng, Yu Min, Yang Shilun, Qiu Linhui, Wang Yu, Xu Aimin, Hoo RLC, Chang Junlei*. Compromised endothelial Wnt/β-catenin signaling mediates the blood-brain barrier disruption and leads to neuroinflammation in endotoxemia. Journal of Neuroinflammation. 2024 Oct 19;21(1):265；

(10) Ma, Yinzhong#; Wang, Lisha#; Yang, Shilun; Liu, Dongyu; Zeng, Yi; Lin, Lilong; Qiu, Linhui; Lu, Jiahao; Chang, Junlei*; Li, Zhihuan* ; The tissue origin of human mesenchymal stem cells dictates their therapeutic efficacy on glucose and lipid metabolic disorders in type II diabetic mice, Stem Cell Research & Therapy, 2021, 12(385)；

(11) Ji, Yabin#; Chen, Yiman#; Tan, Xixi; Huang, Xiaowen; Gao, Qiang; Ma, Yinzhong; Yang, Shilun; Yin, Meifang; Yu, Min; Fang, Cheng; Wang, Yu; Shi, Zhu*; Chang, Junlei* ; Integrated transcriptomic and proteomic profiling reveals the key molecular signatures of brain endothelial reperfusion injury, CNS Neuroscience & Therapeutics, 2024, 30(4)；

（1）畅君雷；杨时伦；马寅仲；朱亚东；左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用；2020-09-16；世界知识产权组织（国际局）；PCT/CN2020/115620；

（2）畅君雷；杨时伦；马寅仲；朱亚东；左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用；2020-09-16；中国；CN202010972345.9；

（3）畅君雷；余敏；胡小燕；杨时伦；一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用；2021-08-27；中国；CN202110994420.6；

（4）畅君雷；杨时伦；李思梦；一种A-FABP蛋白抑制剂及其应用；2021-11-15；中国；CN202111349737.0；

（5）畅君雷；杨时伦；李思梦；一种A-FABP蛋白抑制剂及其应用；2021-12-14；世界知识产权组织（国际局）；PCT/CN2021/137800；

（6）畅君雷；余敏；胡小燕；杨时伦；一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用；2021-12-14；世界知识产权组织（国际局）；PCT/CN2021/137746；

（7）畅君雷；杨时伦；余敏；李思梦；一种分泌抗A-FABP单克隆抗体6C11的杂交瘤细胞株及其用途；2022-06-30；中国；CN202210756655.6；

（8）畅君雷；杨时伦；李思梦；一种A-FABP单克隆抗体2C6及其制备方法和用途；2022-06-30；中国；CN202210756000.9；

（9）畅君雷；杨时伦；李思梦；一种A-FABP单克隆抗体2B8及其制备方法和用途；2022-06-30；中国；CN202210755954.8；

（10）畅君雷；杨时伦；李思梦；余敏；一种分泌抗A-FABP单克隆抗体3G5的杂交瘤细胞株及其用途；2022-06-30；中国；CN202210755900.1；

（11）畅君雷；杨时伦；余敏；李思梦；一种分泌抗A-FABP单克隆抗体4A12的杂交瘤细胞株及其用途；2022-06-30；中国；CN202210755920.9；

（12）畅君雷；杨时伦；李思梦；一种A-FABP单克隆抗体2C6及其制备方法和用途；2022-06-30；世界知识产权组织（国际局）；PCT/CN2022/102637；

（13）畅君雷；杨时伦；李思梦；一种A-FABP单克隆抗体2B8及其制备方法和用途；2022-06-30；世界知识产权组织（国际局）；PCT/CN2022/102639；

（14）何丽庄；徐爱民；廖博雅；畅君雷；杨时伦；李思梦；一种A-FABP中和单克隆抗体及其制备方法和用途；2022-11-17；中国；CN202211439397.5；

（15）Lai Chong Ruby HOO；Aimin XU；Boya LIAO；Junlei CHANG；Shilun YANG；Simeng LI；AN AFABP NEUTRALIZING MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF，2023-11-10，美国，18/506,988；

（16）Lai Chong Ruby HOO；Aimin XU；Boya LIAO；Junlei CHANG；Shilun YANG；Simeng LI；AN A-FABP NEUTRALIZING MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF，2023-11-13，欧洲，EP23209441.7；

（17）畅君雷；余敏；秦齐；杨时伦；冯孟昭；AZD2858化合物在制备脑胶质瘤化疗药物的增效剂中的用途；2024-06-03；中国；CN202410709728.5；

（18）畅君雷；杨时伦；一种A-FABP单克隆抗体3H9及其制备方法和用途；2024-09-10；中国；CN202411263947.1；